News Related to PSMA-positive Metastatic Hormone-Sensitive Prostate Cancer

Related coverage linked through entity extraction aliases.

Novartis reports new Pluvicto data in metastatic hormone-sensitive prostate cancer

May 18, 2026

Novartis reported Phase III PSMAddition data showing Pluvicto plus standard of care cut the risk of PSA progression by 58% in PSMA-positive metastatic hormone-sensitive prostate cancer. Regulatory decisions in the United States, China and Japan are expected in the second half of 2026.

PSMAddition shows rPFS benefit for 177Lu-PSMA-617 triplet in PSMA-positive mHSPC

Apr 06, 2026

Phase 3 PSMAddition showed that adding 177Lu-PSMA-617 to ADT plus an ARPI improved radiographic progression-free survival in PSMA-positive mHSPC. Health-related quality of life and pain were largely maintained.